PMID- 36524462
OWN - NLM
STAT- MEDLINE
DCOM- 20221226
LR  - 20230105
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
VI  - 34
IP  - 12
DP  - 2022 Dec
TI  - Primary renal neuroendocrine neoplasms: A systematic literature review, report of 
      four local cases, and original survival analysis of 63 patients from a national 
      registry 2012-2018.
PG  - e13215
LID - 10.1111/jne.13215 [doi]
AB  - Primary renal neuroendocrine neoplasms (NEN) are rare. We aimed to conduct a 
      systematic review, present local cases, and analyse data from the England's 
      National Cancer Registration and Analysis Service (NCRAS) to provide 
      comprehensive evidence on clinical experience, incidence, and survival to better 
      characterize these tumours. First, a systematic review using the Preferred 
      Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method; second, 
      a synthesis of local cases; and, finally, a retrospective population-based cohort 
      analysis of renal NEN recorded between 2012 and 2018 on NCRAS were performed. 
      Kaplan-Meier estimator was used to calculate overall survival and Cox 
      proportional hazard regression to identify prognostic factors. Systematic review 
      identified 48 articles and the evidence was summarized and presented. We reported 
      data from four local cases presenting with abdominal and back pain but without 
      carcinoid syndrome. In population-based analysis, we identified 63 cases of renal 
      NEN between 2012 and 2018 from the registry. Age-standardized incidence was 
      0.09-0.32 per million with a median age of 64 years (interquartile 
      range = 48-72 years). Survival was worse in males and those aged 64 years and 
      over. Five-year survival for renal neuroendocrine tumours (NET) was 69.8% (95% 
      confidence interval = 66.6-72.7) and neuroendocrine carcinomas (NEC) was 38.4% 
      (95% confidence interval = 34.6-42.0). No independent predictive factor was 
      identified in the multivariable analyses. We have given a systematic review of 
      evidence, published local experience, and reported incidence and survival of 
      renal NEN in England for the first time. We have provided clinicians with 
      evidence on diagnosis and proposed a treatment algorithm of theses rare tumours. 
      The incidence and median age of presentation in England is similar to other 
      published series. Renal NET has better survival than renal NEC as expected. A 
      uniform classification system would reduce inconsistencies in reporting and 
      standardize treatment decisions for this neoplasia.
CI  - (c) 2022 British Society for Neuroendocrinology.
FAU - Paisey, Sangeeta A
AU  - Paisey SA
AUID- ORCID: 0000-0002-4304-1940
AD  - Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
AD  - King's Health Partners ENETS Centre of Excellence, London, UK.
FAU - Weerasuriya, Scott
AU  - Weerasuriya S
AUID- ORCID: 0000-0002-5205-6095
AD  - King's Health Partners ENETS Centre of Excellence, London, UK.
FAU - Palmer, Kieran
AU  - Palmer K
AUID- ORCID: 0000-0003-3710-1588
AD  - Barts Cancer Centre, St Bartholomew's Hospital, London, UK.
FAU - White, Benjamin E
AU  - White BE
AUID- ORCID: 0000-0002-8705-7581
AD  - Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
FAU - Srirajaskanthan, Rajaventhan
AU  - Srirajaskanthan R
AUID- ORCID: 0000-0001-9835-8681
AD  - King's Health Partners ENETS Centre of Excellence, London, UK.
FAU - Chandrakumaran, Kandiah
AU  - Chandrakumaran K
AUID- ORCID: 0000-0003-3547-775X
AD  - Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
FAU - Ramage, John K
AU  - Ramage JK
AUID- ORCID: 0000-0003-4824-6600
AD  - Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
AD  - King's Health Partners ENETS Centre of Excellence, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20221216
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Retrospective Studies
MH  - Prognosis
MH  - *Neuroendocrine Tumors
MH  - *Carcinoma, Neuroendocrine/diagnosis
MH  - Survival Analysis
MH  - Registries
OTO - NOTNLM
OT  - renal neuroendocrine carcinoma
OT  - renal neuroendocrine neoplasm
OT  - renal neuroendocrine tumour
EDAT- 2022/12/17 06:00
MHDA- 2022/12/27 06:00
CRDT- 2022/12/16 04:55
PHST- 2022/10/02 00:00 [revised]
PHST- 2022/07/17 00:00 [received]
PHST- 2022/10/13 00:00 [accepted]
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2022/12/27 06:00 [medline]
PHST- 2022/12/16 04:55 [entrez]
AID - 10.1111/jne.13215 [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2022 Dec;34(12):e13215. doi: 10.1111/jne.13215. Epub 2022 Dec 
      16.